Short term response is predictive of long term response to acetylcholinesterase inhibitors in Alzheimer’s disease: A starting point to explore Bayesian approximation in clinical practice by Rota, Eugenia et al.
Bioinformation by Biomedical Informatics Publishing Group  open access 
www.bioinformation.net      Hypothesis   
______________________________________________________________________ 
ISSN 0973-2063 
Bioinformation 2(2): 39-42 (2007) 
Bioinformation, an open access forum 
© 2007 Biomedical Informatics Publishing Group 
39
 
Short term response is predictive of long term 
response to acetylcholinesterase inhibitors in 
Alzheimer’s disease: A starting point to explore 
Bayesian approximation in clinical practice 
 
 
Eugenia Rota
1*, Patrizia Ferrero
2, Rita Ursone
2, Giuseppe Migliaretti
3 
 
1 Neurology Unit, S. Croce Hospital, Italy; 
2 Department of Neuroscience, University of Turin, Italy; 
3  Department of Public Health and 
Microbiology, University of Turin, Italy; *Eugenia Rota - Email: eugenia_rota@yahoo.it; Phone: 39 0174 550593; Fax: 39 0174550539; 
* Corresponding author 
 
received July 31, 2007; revised August 07, 2007; accepted August 11, 2007; published online August 16, 2007 
 
Abstract: 
This study was aimed at identifying, in 203 patients with Alzheimer’s disease followed during long-term treatment with 
Acetylcholinesterase inhibitors (ChEIs), the predictive factors of the clinical response among cognition (MMSE), 
functioning (BADL and IADL) measures and age and gender at the baseline (T0). The ANCOVA test showed a 
significant association between MMSE scores at time T0 and T3, and the variation T9 to T0, T15 to T0 and T21 to T0 of 
the MMSE scores, using also gender, age and drug as covariates. The significance was higher for the patients affected by 
mild dementia. Regarding functional activities, a significant relationship was detected, by the ANCOVA test, only 
between the scores at T3 and the variation T15 to T0 for BADL, and the variation T9 to T0, T15 to T0 for IADL, 
respectively. Our results confirm, in a real world setting, that ChEIs provide long-term cognitive benefit, which is 
correlated to, and predictable by, the short-term response (within the third month) as well as the cognitive status 
(evaluated by means of the MMSE) at the beginning of the treatment. These factors should be the basis of any 
cost/effectiveness algorithm in health economic decision models. 
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Background: 
Alzheimer's disease (AD) is a progressive disease of the 
brain. It is a common type of dementia in the elderly, 
which can have devastating outcomes on the diagnosed 
patient, on the caregivers and family, and on society at 
large. Although the amyloid β-mediated neurotoxicity is 
considered the pivotal pathophysiological factor, an 
inflammatory response has been hypothesized, and some 
processes involved in the physiologic modulation of the 
immune response are emerging as potential biological 
prognostic factors.
 [1] 
 
Acetylcholinesterase inhibitors (ChEIs) have proved to 
be an effective treatment in mild to moderate AD, by 
enhancing cholinergic neurotransmission.
 [2] Despite the 
large amount of literature demonstrating the efficacy and 
safety of ChEIs therapy in AD, clear evidence is lacking 
about patterns and predictors of the clinical response, 
which is a topic of crucial interest, clinically and from an 
economical point of view. In fact, the non-response 
represents a potential waste of the limited funds available 
to health management systems. Baseline measures, such 
as degree of cognitive impairment, rate of disease 
progression, older age, smoking habit, and the presence 
of concurrent vascular risk factors, are able to affect the 
clinical response. Some of these parameters (age, 
cerebrovascular disease, as well as hippocampal atrophy) 
may act through structural mechanisms, smoking 
through chemical ones.
 [3] The presence of subcortical 
vascular lesions has been reported not to significantly 
affect the response to ChEIs. [4] 
 
Another question at issue is the reproducibility, in a “real 
world” setting, of the results achieved in controlled 
clinical trials, where the selection of AD patients, based 
on very restrictive criteria, makes the cohorts more 
homogeneous and generally younger with respect to 
everyday clinical practice. [5] Recently, the Italian 
Ministry of Health-sponsored “Cronos Project” 
(conceived to administer ChEIs free of charge to all mild 
to moderate AD subjects) seems to confirm that also non 
selected AD patients with mild to moderate dementia, 
living at home, benefit from ChEIs treatment. [6, 7] 
 
Taken together, these observations show the need of a 
novel approximation approach for posterior 
expectations of real valued functions, given observed 
data, which may allow clinical practitioners to obtain a 
clearer view of the expected net benefit of a treatment. 
Therefore, encouraging clinical data collection from 
“real world” patients out of randomized clinical trials 
will give biostatisticians the information they need to 
build up an algorithm minded to give the most Bioinformation by Biomedical Informatics Publishing Group  open access 
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certainty in the cost/effectiveness decision-making 
process. This is of pivotal importance in AD, a disease 
that drains millions of dollars in health costs worldwide 
every year. 
 
Description: 
We administered ChEIs to a cohort of 203 naïve patients 
(91 males and 112 females), mean age: 72.4 ± 8.9 years, 
referred to our Alzheimer’s Evaluation Unit from 
October 2000 to December 2002, and eligible for the 
“Cronos Project” - diagnosis of probable AD according 
NINCDS ADRDA criteria [8], MMSE score: 14 to 24, 
onset of cognitive disorders between 40 and 90 years of 
age, absence of comorbid diseases (asthma, cardiac 
rhythm disturbances, gastroduodenal ulcer, hepatic or 
renal failure), able to contraindicate the ChEIs therapy- 
were enrolled. Based on our data, we tried to identify, in 
a “real world” setting, the predictive factors of the 
clinical response among cognition (MMSE) [9] and 
functioning (BADL and IADL)
 [10]
 measures and age 
and gender at the baseline. 
 
We excluded from the study all subjects (63), enrolled in 
the “Cronos Project” over the same period, but 
previously treated with ChEIs. The patients were 
commenced on either Donepezil (136 subjects, 67 
percent), or Rivastigmine (52, 25 percent) or 
Galantamine (15, 8 percent). They could be also treated 
with antipsychotics or other drugs acting on the nervous 
system, if needed to control behavioral and 
psychological symptoms.  
According to the study protocol, periodic clinical and 
multi-dimensional assessments were performed at the 
baseline (T0) and after months 1 (T1), 3 (T3), 9 (T9), 15 
(T15), 21 (T21) and 30 (T30), on the patients not 
withdrawn; efficacy on the cognitive and functional 
aspects was evaluated respectively by MMSE, and by 
BADL and IADL. In the patients lost at the follow-up, 
the specific reasons for withdrawal were different (lack 
of tolerability or compliance, deaths) and found out only 
when reported to the physicians by the caregivers. 
 
In order to avoid an artificial categorization of the 
patients, no MMSE cut-off score was set for defining the 
clinical response, which was evaluated based on the time 
course change of the MMSE and BADL-IADL scores 
with respect to the baseline. 
 
The time course variation of the cognitive and functional 
performances of our patients during the ChEIs treatment 
was assessed (by means of the ANOVA for repeated 
measures) for MMSE scores, and for BADL and IADL 
scores respectively, at T0, T3, T9, T15 and T21. Data 
were analyzed according to previously published 
methods. [6] 
 
The MMSE and BADL-IADL scores (means ± standard 
deviations, median values) of the patients from the 
baseline to T30 are shown in figure 1. As expected, the 
sample size waned during time until T30.  
 
 
 
Figure 1:  MMSE (for the total sample and for subgroups with MMSE, respectively, > 18 or  ≤ 18 at T0), BADL and 
IADL scores (means, standard deviations, median values) over time, at T0, T1, T3, T9, T15, T21 and T30; number 
(N°) and percentage (%) of patients with respect to the baseline (T0)  Bioinformation by Biomedical Informatics Publishing Group  open access 
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Compared with pre-treatment T0, average MMSE scores 
in all groups showed a statistically significant increase at 
T3 (p<0.005, df:2; F: 5.23) and at T9 (p< 0.001, df:3; F: 
7.61) and a decrease afterwards, at T15 (p< 0.001, df:4; 
F: 39.27) and T21 (p< 0.001, df:5; F: 60.52).  
 
The BADL scores decreased, showing, a borderline 
statistical significance (p: 0.049; df:2; F: 3.06) at T3, but 
higher (p≤ 0.001) from T9 onwards. Regarding the IADL 
scores, they reduced significantly (p< 0.001), in each 
evaluation session, from T3 to T21. 
 
As far as the type of drug is concerned, the scarce 
number of patients treated with galantamine, compared 
to those receiving donepezil and rivastigmine, made the 
evaluation of this covariate unreliable. For the two 
subgroups, affected respectively by “mild” (MMSE > 18 
at T0) and “moderate” dementia (MMSE ≤ 18 at T0), the 
MMSE scores at time T0 and T3 correlated significantly, 
by the ANCOVA test, with the variation T15 to T0 and 
T21-T0 (p≤ 0.001) only in the “mild” patients; this was 
not confirmed for patients with “moderate” dementia. 
 
As regards BADL measures (the afore mentioned limits 
of the analysis permitting), the only statistically 
significant (p≤ 0.05) association was found, by the 
ANCOVA test, between the scores at T3 and the 
variation T15 to T0.  
 
The correlation of IADL scores at time T0 and T3 with 
the variation T9 to T0 revealed a high statistical 
significance (p≤ 0.001), which became lower (p≤ 0.05) 
with the variation T15 to T0, and borderline (p< 0.053 
for T3 and 0.04 for T0) with that one T21 to T0. 
 
Our results confirm, in real outpatient life conditions, 
that ChEIs provide long-term (nine months) cognitive 
benefit in “mild” to “moderate” AD patients. Then, the 
efficacy of this treatment, demonstrated in the controlled 
clinical trials is reproducible in a “real world” setting, as 
suggested by previous authors. [6, 7] Although AD 
patients treated in the clinical practice and enrolled in 
our study were different (older and more likely to have 
comorbid disorders and to use other drugs acting on the 
nervous system) from those included in randomized-
controlled clinical trials, they seemed to benefit from 
ChEIs to the same extent. 
 
Some shortcomings should be taken into account, that 
are typical of the general practitioner’s world, firstly the 
large dropout rate. Although there may be the 
assumption that only subjects who appeared to be 
responding to treatment actually continued on treatment, 
and those who continued on treatment showed a 
response, this sort of a “circularity of argument” is 
intrinsic to this kind of open label follow up studies. 
Nevertheless, the finding of a significant association 
between the MMSE scores at time T0 and T3 and the 
variation T15 to T0 and T21 to T0 seem to be clearly 
demonstrated by our results.  
 
This relationship was confirmed only in presence of 
MMSE >18 at the baseline, suggesting that the initial 
cognitive status and the early response (at three months) 
may reliably predict the long-term one only in the “mild” 
AD patients. On the contrary, in the moderate and 
moderate severely affected AD patients, the long-term 
response did not seem to be clearly related to, and 
predictable by, the early clinical benefit. Consequently, 
the degree of cognitive impairment appeared the most 
influent factor upon the long-term response; the less 
cognitively compromised the patients were at the 
beginning of the treatment with ChEIs, the more strictly 
associated their long-term response was to the short-term 
one. These factors should be taken into account in 
evaluating any cost/effectiveness ratio in a decision-
making setting.  
 
The relationship between MMSE scores at baseline and 
the clinical improvement in “mild” patients highlights 
the importance of appropriate diagnostic methods to 
identify subjects who have the earliest clinical signs of 
AD, in order to begin the ChEIs therapy as soon as 
possible. On the other hand, the highly significant 
correlation between the short-term response and the 
long-term one, suggests that, if a cognitive improvement 
is not detectable within the first 2 to 3 months, the ChEIs 
treatment should be reconsidered. For instance, it may be 
reasonable to switch the non-responder to another one of 
the three ChEIs. In fact, a beneficial effect was 
demonstrated in about the half of the subjects exposed to 
a second ChEI [11, 12], since the response to a first ChEI 
was not predictive of that one to another.
 [11, 12] Based 
on our results, it seems not useful to wait for a clinical 
benefit of one ChEI longer than three months; after this 
period, the clinician has to judge the efficacy of the 
therapy and eventually switch non-responders to another 
treatment protocol.  
 
It has been suggested that the optimal decision is the 
decision that yields the highest expected net benefit, 
according to current information. [13] Thus, any new 
data will update our knowledge concerning the 
parameters of interest, then, we will be able to make a 
revised decision based on the new information. This will 
lead us to choose the treatment with the highest expected 
benefit.   
 
Therefore, the expected value of sample information is 
the difference between the expected value of a decision 
made after “real world” data have been collected and 
expected value of a decision made now, with only 
information related to currently available clinical trials. It 
is this process of updating the probability distributions, 
given new data that makes the process inherently 
Bayesian. Bayesian updating could be undertaken for 
using Markov Chain Monte Carlo methods (example, an 
application in Win-BUGS: http://www.mrc-
bsu.cam.ac.uk/bugs/welcome.shtml) to allow sampling 
from the posterior distribution. 
 
Health economists, modelers and statisticians should be 
able to apply results from medical practice in the context 
of the expected value gained by obtaining “real world” 
sample information before making a decision on any 
single patient, such raising the efficiency of research Bioinformation by Biomedical Informatics Publishing Group  open access 
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investments in terms of cost/effectiveness and patient’s 
quality of life. 
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